
· Executive Brief
National Birth Defects Prevention Month 2026
Use the observance to test whether prevention, readiness, escalation, and learning operate as one connected system.

Leadership signal
Recognition becomes useful when leaders inspect the real route.
A safety-focused observance is a useful point to compare policy with real work. Include frontline teams, facilities, operations, clinical leadership, and other relevant partners. Identify where the process depends on memory, informal workarounds, or an unowned handoff.
Start by distinguishing what is known from what the organization still needs to learn. A campaign plan, communication volume, or meeting count does not establish that a route is usable. Leaders need direct listening, clear ownership, locally defined measures, and a method for keeping exceptions visible.
Executive opening
Birth defects prevention is a referral and follow-through problem as much as a clinical one
National Birth Defects Prevention Month draws attention to a long chain of services that rarely sits under one owner. It runs from care before pregnancy, through medication review and prenatal testing, to newborn screening and early intervention after birth. Each link depends on the one before it. When any link fails quietly, the opportunity to prevent harm or limit its effects can pass without anyone noticing. Most of these links also cross organizational lines, between clinics, pharmacies, hospitals, public health programs and community agencies.
Timing is the clearest example. A four-country study examined pregnancies among women using antiseizure medications.[6] Starting high-dose folic acid 1 to 12 weeks before pregnancy was associated with fewer major congenital anomalies, 2.6% versus 4.8%.[6] Yet only 3.8% of eligible pregnancies had a high-dose folic acid prescription started in that window.[6] Starting after pregnancy onset was not associated with lower risk.[6] The benefit depends on a conversation that must happen before many people seek prenatal care.
The chain after birth shows similar losses. Among 7,169 very preterm infants in Massachusetts, 84% were referred to early intervention, 71.3% were evaluated and 64.5% received an individualized family service plan.[1] Each step loses families, and the losses are larger for some racial and ethnic groups.[1] Those losses occur after the system has already identified the infant as needing support, which makes them a follow-through problem rather than a detection problem.
The sections below summarize peer-reviewed evidence on medication exposure, preconception care, folic acid use, newborn screening, early intervention, equity, the genetic counseling workforce and communication. They sit beside the executive guidance already on this page. Their aim is to help leaders decide which handoff in the prevention and follow-up chain deserves attention first. Most of the studies are single-country or single-site, so each finding is presented with its setting and limits.
Current evidence
What the research shows about exposure, prevention and detection
Medication exposure is common among people who could become pregnant. A U.S. national survey analysis of women aged 20 to 44 from 2009 to 2020 found that any prescription medication use among pregnant women rose from 28.5% to 37.1%.[5] The authors report that medications with potential fetal risk were commonly used, including by non-pregnant women not using contraception.[5] Antidepressants were a particular focus, which links medication safety with maternal mental health care.[5] The authors call for continued monitoring and greater awareness of medication safety during pregnancy.[5]
Folic acid prevention is well established but unevenly delivered. One study cites evidence that periconceptional folic acid supplementation reduces neural tube defects by 72% to 86%.[10] Yet among 337 pregnant women at an Ethiopian teaching hospital, only 8.9% showed good knowledge of periconceptional supplementation.[10] Knowledge was higher with higher education, current family planning use and planned pregnancy.[10] Those factors describe people who already have regular contact with services, which suggests where outreach is weakest.
Deficiency and adherence remain problems even when supplements are available. In a Brazilian referral hospital cohort of 1,052 pregnant women, folic acid deficiency prevalence was 8.4%.[11] Deficiency was associated with lack of supplementation, absence of a partner and assessment during the second trimester.[11] Among 303 postpartum mothers in Nepal, compliance with iron and folic acid supplementation was 48.2%.[12] Only 38.6% of the deficient women in the Brazilian cohort reported using supplementation.[11] Supply alone does not ensure use. Counseling, reminders and follow-up contacts are part of the prevention service, not extras.
Newborn screening shows what population coverage can achieve. In southwestern Iran, 403,833 of 450,542 newborns (89.96%) were screened for hearing loss between 2019 and 2023.[4] Permanent hearing loss was confirmed in 986 infants, a prevalence of 2.44 per 1,000 live births.[4] Prevalence was 11.6 per 1,000 among infants admitted to neonatal intensive care, compared with 1.05 among well-baby nursery infants.[4] Overall, 71.39% of affected infants had at least one recognized neonatal risk factor.[4] Risk-based follow-up therefore depends on accurate risk documentation at discharge.
These studies differ in country, population and outcome, so they cannot be combined into one estimate. Together they show a consistent pattern. Effective prevention and detection tools exist, but their value depends on reaching people at the right time and completing each follow-up step.[4][6]
Figure 1
Prevention and follow-up steps are completed unevenly
Percent of eligible people or infants completing a prevention or follow-up step, as reported in each study. Values are copied from the cited studies [1], [2], [6], [10], [12]; none is estimated.
Data note. These values come from different countries, populations, years and definitions, so this is an indirect comparison; the bars show where prevention and follow-up steps fall short, not how one service compares with another.
Limitation. Each value has its own denominator; the folic acid figures come from single-site or single-city studies, and the early intervention figures come from one U.S. state.
Figure data (5 rows)
| Measure | Value | Population, setting and year as reported | Source |
|---|---|---|---|
| High-dose folic acid started 1 to 12 weeks before pregnancy | 3.8% | 521 of 13,619 eligible pregnancies among women using antiseizure medications, Denmark, Iceland, Norway and Sweden, 1997 to 2020 | [6] |
| Good knowledge of periconceptional folic acid | 8.9% | 337 pregnant women at one Ethiopian teaching hospital antenatal clinic, 2024 | [10] |
| Compliance with iron and folic acid supplementation | 48.2% | 303 postpartum mothers in Bharatpur, Nepal | [12] |
| Substance-exposed newborns enrolled in early intervention after referral | 49.5% | 2,775 of 5,602 referred newborns, Massachusetts, 2013 to 2020 | [2] |
| Very preterm infants with a signed family service plan | 64.5% | 7,169 infants born at less than 32 weeks, Massachusetts, 2012 to 2019 | [1] |

Continuum of care
Where the prevention and follow-up chain breaks
The first break often comes before pregnancy. In the antiseizure medication study, high-dose folic acid was started 13 to 52 weeks before pregnancy in 5.7% of pregnancies.[6] It was started 1 to 12 weeks before in 3.8%, and in the 12 weeks after onset in 14.4%.[6] The largest share started in the window not associated with lower risk.[6] That pattern points to a timing problem in medication review, not only a prescribing problem. The window opens before many people have a pregnancy-related visit, so the review must happen in neurology, primary care or pharmacy.
After birth, the chain moves from screening to diagnosis to services. In the Iranian hearing program, 7,491 infants (1.85%) were referred for diagnostic assessment after screening.[4] The authors stress targeted follow-up for high-risk populations and early intervention.[4] Each referral creates a handoff that needs an owner until diagnosis and, when needed, treatment are complete. Screening programs that track only the initial test cannot show whether referred infants reached a diagnosis.
Early intervention shows how much is lost between referral and enrollment. Among 6,565 substance-exposed newborns in Massachusetts, 85.3% were referred to early intervention, but only 49.5% of those referred enrolled.[2] Newborns with a diagnosis of neonatal abstinence syndrome were more likely to enroll than those without, 53.2% versus 38.2%.[2] The authors describe this as a referral-to-enrollment gap.[2] Among infants and toddlers without known substance exposure, referral rates were lower (34.6%), but enrollment among those referred was higher (56.7%).[2]
Early diagnosis does not guarantee early services. In a pilot program for infants diagnosed with fragile X syndrome in the newborn period, only half were enrolled in their state’s early intervention program by their first birthday.[3] All were eligible and had received instructions for accessing services.[3] The authors call for more attention to the referral process for infants diagnosed with neurogenetic conditions.[3] Occupational therapy was the most accessed service, used by 33% of infants, followed by physical therapy at 27%.[3]
These gaps share a structure. A test or referral is completed in one setting, and the next step depends on another organization, a family’s capacity and a clear route between them.[1][2] Leaders should ask which team confirms that a referred infant actually reached evaluation and services, and how long the system waits before following up. A defined follow-up interval, with escalation when it passes, turns an open referral into a managed one.
Figure 3
Why the pathway breaks
People
- Limited genetic counseling capacity relative to testing
- Low public awareness of nurse practitioner and pharmacist roles
- No named owner for referral follow-up
Process
- Folic acid started after pregnancy onset rather than before
- Referrals made without confirmation of evaluation
- Medication review without pregnancy planning conversation
Technology
- No linked record between birth hospital and early intervention
- Long turnaround for genetic testing
- Screening results not tracked to diagnosis
Environment
- Families facing transportation and scheduling barriers
- Wariness of systems among families affected by substance use
- Unplanned pregnancies limiting preconception contact
Policy
- Out-of-pocket costs for preconception care
- Variable reimbursement for genetic testing and counseling
- Eligibility rules that do not trigger outreach
Measurement
- Cascade steps not measured beyond referral
- Results not stratified by race, ethnicity or payer
- Medication exposure among non-pregnant patients not tracked
Unranked qualitative cause-and-effect diagram for the outcome in the box: People at risk and infants with identified conditions do not complete preconception prevention, diagnostic follow-up or early intervention enrollment Causes are assembled from the cited literature [1], [2], [3], [4], [5], [6], [7], [12], [15]; categories are not weighted and their order carries no meaning.
Data note. Qualitative; no frequencies are implied.
Limitation. Causes drawn from published studies may not all apply locally; validate them with frontline teams.
Figure data (6 rows)
| Category | Causes drawn from the cited literature |
|---|---|
| People | Limited genetic counseling capacity relative to testing; Low public awareness of nurse practitioner and pharmacist roles; No named owner for referral follow-up |
| Process | Folic acid started after pregnancy onset rather than before; Referrals made without confirmation of evaluation; Medication review without pregnancy planning conversation |
| Technology | No linked record between birth hospital and early intervention; Long turnaround for genetic testing; Screening results not tracked to diagnosis |
| Environment | Families facing transportation and scheduling barriers; Wariness of systems among families affected by substance use; Unplanned pregnancies limiting preconception contact |
| Policy | Out-of-pocket costs for preconception care; Variable reimbursement for genetic testing and counseling; Eligibility rules that do not trigger outreach |
| Measurement | Cascade steps not measured beyond referral; Results not stratified by race, ethnicity or payer; Medication exposure among non-pregnant patients not tracked |
Access
Making preconception care, genetic services and follow-up reachable
Preconception care reaches few people because many do not know it exists. In an Australian discrete choice experiment, 485 adults completed the survey, and 67% had either not heard of preconception care or were unsure.[7] Respondents strongly preferred face-to-face care, particularly from specialist obstetricians.[7] Lower out-of-pocket costs and incentives were also important drivers of preference.[7] The authors conclude that reducing costs and offering incentives may encourage engagement with preconception services.[7]
Those preferences have capacity implications. The same study highlights low awareness of the skills of nurse practitioners and pharmacists, who are well placed to deliver preconception care in primary care.[7] If demand concentrates on specialists, access will be limited by specialist supply. Building visible preconception roles in primary care and pharmacy can widen the entry points. Those roles also fit naturally with medication review, contraception visits and routine prescription refills.
People planning pregnancy already use the health system, but not always in ways that support prevention. In an Australian national survey of 874 women aged 18 to 49, 7.4% were trying to conceive and 5.2% planned to within 12 months.[8] Women trying to conceive were more likely to consult a traditional Chinese medicine practitioner (odds ratio 2.66) or a dietitian (odds ratio 2.11).[8] The authors call for a whole-of-health-system approach to preconception care.[8] People planning pregnancy may first raise the topic with practitioners outside conventional medical settings, which is a reason to build referral links with them.
Access to genetic testing and counseling also varies. Across 46 European expert epilepsy centers, whole-exome sequencing was available in 85% and whole-genome sequencing in 59%.[15] Turnaround times for standard testing were most commonly between 1 and 6 months.[15] The survey found considerable variation in access to genetic counseling, reimbursement and multidisciplinary team organization.[15] For conditions where test results guide early decisions, a wait of several months is itself an access barrier.
Antenatal contact is a key access point for supplementation. In the Nepal study, having more than eight antenatal care visits was associated with higher compliance (odds ratio 3.465).[12] Good knowledge about anemia (odds ratio 5.554) and about iron and folic acid supplementation (odds ratio 2.442) was also associated with higher compliance.[12] Access to repeated, informative contact matters as much as access to the supplement itself. Antenatal visit schedules, reminder systems and transport support all influence how many contacts a person actually has.
Executive guidance · System route
Map the path from first contact to verified follow-through.
Use this route as a discussion framework. Replace each stage with the organization’s approved process, qualified roles, current service capacity, and applicable requirements. Do not infer a clinical protocol from the observance title.
The route at a glance
- Identify the concern
- Activate prevention
- Protect continuity
- Escalate and respond
- Review and improve
Reliability rule: Every stage needs a named owner, an observable status, an approved escalation path, and a defined signal that shows whether responsibility moved or remained unresolved.
Identify the concern
Define approved ways to recognize and report a concern without asking unqualified staff to make clinical or legal determinations.
Activate prevention
Make locally approved controls, tools, education, and responsibilities visible where the work occurs.
Protect continuity
Clarify how information, questions, and unresolved needs remain owned across settings, time periods, teams, and community partners relevant to the local route.
Escalate and respond
Route the concern to the qualified owner, acknowledge receipt, and preserve visibility until the next action is accepted.
Review and improve
Examine exceptions, near misses, workarounds, and delays using a learning approach and transparent action ownership.
Figure 2
The system route as one flow
The five stages of the system route described in this brief, drawn as one flow with a learning loop back to the start. The stages are the page’s original executive guidance, not a clinical protocol.
Data note. Shows sequence and handoffs only; it carries no counts or rates.
Limitation. Local processes may add, merge or reorder stages under organizational policy.
Figure data (5 rows)
| Stage | What the stage requires |
|---|---|
| Identify the concern | Define approved ways to recognize and report a concern without asking unqualified staff to make clinical or legal determinations. |
| Activate prevention | Make locally approved controls, tools, education, and responsibilities visible where the work occurs. |
| Protect continuity | Clarify how information, questions, and unresolved needs remain owned across settings, time periods, teams, and community partners relevant to the local route. |
| Escalate and respond | Route the concern to the qualified owner, acknowledge receipt, and preserve visibility until the next action is accepted. |
| Review and improve | Examine exceptions, near misses, workarounds, and delays using a learning approach and transparent action ownership. |
Equity and trust
Losses along the chain are not shared equally
The Massachusetts early intervention cascade shows inequity at every step. Non-Hispanic Black very preterm infants had lower rates of referral (81.3%), evaluation (62.5%) and a signed family service plan (55.0%).[1] The comparable rates for non-Hispanic White infants were 84.6%, 75.4% and 68.4%.[1] The adjusted odds of evaluation for Black infants were 0.57 compared with White infants.[1]
Those differences narrowed when the analysis adjusted for infant and family social variables.[1] That finding suggests social conditions explain part of the gap, which places transportation, scheduling, language and trust within the scope of the solution. The authors conclude that targeted structural interventions at each step can close the equity gap.[1] For health systems, that means examining each step separately rather than reporting a single referral rate.
Substance exposure adds another dimension. Substance-exposed newborns without a neonatal abstinence syndrome diagnosis enrolled in early intervention at lower rates than those with the diagnosis.[2] Some families affected by substance use may be wary of systems they associate with surveillance or child protection. Referral routes that feel supportive rather than punitive may matter for enrollment. Peer support and care coordinators with experience in recovery services may help families take the next step.
Partner involvement and household circumstances also shape prevention. In the Brazilian cohort, absence of a partner was associated with folic acid deficiency.[11] In an Indonesian primary care survey of 100 men planning marriage or conception, 46% showed high involvement in preconception care, 28% moderate and 26% low.[9] Knowledge, attitudes and spousal communication were key factors in engagement.[9] Prevention outreach that ignores partners and household support may miss people who are most at risk.
Education and pregnancy planning are recurring markers. In the Ethiopian study, higher education was strongly associated with better folic acid knowledge (adjusted odds ratio 5.13), and planned pregnancy also mattered (adjusted odds ratio 3.59).[10] People with unplanned pregnancies or less education are likely to need prevention offered through routine contacts rather than waiting for them to seek it. Because race and ethnicity and education were each associated with these gaps, leaders can stratify every step of the chain by both.[1][10] Sharing those results with community partners can build the trust that referral completion depends on.

Human infrastructure
The genetic counselors and partners who keep the chain connected
Genetic counselors are central to prenatal and newborn follow-up, and the profession is changing. A survey of 514 genetic counselors with an average of 9.5 years of experience explored interest in a doctoral degree.[13] Most (69.1%) supported a doctorate for experienced counselors, and 37.4% were interested in pursuing one.[13] About half (48.6%) thought a doctorate could reduce opportunities for master’s-trained counselors.[13] Perceived benefits included stronger research skills (85.9%) and access to faculty positions (83.1%).[13] Those views will shape the future supply and roles of counselors.
Training content is also evolving. Leadership from 45 of 65 North American genetic counseling programs (69.2%) completed a survey on cell and gene therapy education.[14] Lack of time in students’ schedules (28.9%) was the most frequent barrier to adding training.[14] Access to professionals in the field (53.3%) was the most frequent facilitator.[14] The authors suggest that a centralized resource could improve education in this area.[14]
Multidisciplinary organization shapes what genetic counselors can deliver. The European epilepsy center survey found considerable variation in multidisciplinary team organization and access to genetic counseling.[15] Testing capacity without counseling capacity can leave families with results they cannot interpret or act on. Leaders should plan the two together. Counseling time should be budgeted per test ordered, not added after demand has grown.
Other roles carry parts of the chain. Nurse practitioners and pharmacists are well placed to deliver preconception care but are not widely recognized by the public for that role.[7] In the fragile X pilot, an intervention team gave families instructions for accessing early intervention, yet only half enrolled by age one.[3] Instructions alone may not be enough without someone who follows up on the referral. A navigator or liaison who checks enrollment status can turn a referral into a service.
Health systems can treat these roles as one connected workforce. Genetic counselors, maternal-fetal medicine teams, pharmacists, newborn screening coordinators and early intervention liaisons each own a handoff. Naming who owns each step, and how much time that role has, is the first step to closing referral gaps. The same review should ask whether these roles reflect the languages and communities of the families served.
Executive guidance · Operating dashboard
Measure whether the operating route works as intended.
Do not publish a number until the organization defines its numerator, denominator where relevant, owner, source system, exclusions, review cadence, and limits. The candidates below are management prompts, not benchmarks or reported results.
Four operating signals
Each signal pairs an executive question with one candidate local measure, set out below.
Executive guidance · Signal
Prevention reliability
Are approved preventive steps usable and consistently supported in the real work environment?
- Candidate local measure
- Locally defined control checks, barriers, exceptions, and corrective-action status.
Executive guidance · Signal
Readiness
Can the right team, tool, information, and backup be reached when needed?
- Candidate local measure
- Readiness checks, unavailable resources, response barriers, and escalations.
Executive guidance · Signal
Continuity across settings
Can people and teams see who owns the next step when responsibility crosses a setting or service?
- Candidate local measure
- Locally defined transition acknowledgment, unresolved work, repeat contacts, escalation, and experience feedback.
Executive guidance · Signal
Learning system
Are recurring patterns translated into owned improvements?
- Candidate local measure
- Review completion, assigned actions, overdue actions, verified changes, and shared learning.
Figure 4
The operating system behind the dashboard
The four operating signals from this brief’s dashboard, each tied to the candidate owner named in the executive scorecard, around one accountable route. Drawn from the page’s original executive guidance.
Data note. Structural diagram; no measured values.
Limitation. Owners are candidates to be confirmed locally.
Figure data (4 rows)
| Operating signal | Candidate owner |
|---|---|
| Prevention reliability | Executive sponsor and operational lead |
| Readiness | Operational owner and participating teams |
| Continuity across settings | Sending and receiving owners |
| Learning system | Improvement owner and executive sponsor |
Executive guidance · Handoff workflow
Keep work owned when it crosses a boundary.
A handoff is reliable only when the sending party knows who is expected to receive the work, the receiving party acknowledges responsibility, and any unresolved exception remains visible. Local policy and qualified judgment control the actual process.
How responsibility moves
Lane A
From message to accepted ownership
- Confirm the approved message and intended audience.
- Publish the actual entry point and receiving role.
- Acknowledge receipt using the locally approved method.
- Escalate when ownership or response remains unclear.
Lane B
From accepted ownership to verified follow-through
- Record the next accountable owner and visible status.
- State who owns the next contact and how the person or family can identify the approved next step.
- Keep unresolved work visible across boundaries.
- Confirm closure or document the continuing exception.
Executive guidance · Executive scorecard
Ask questions that connect intent, ownership, and results.
The scorecard keeps review focused on decisions. Leaders should set definitions locally, examine variation without overclaiming cause, and pair quantitative signals with the experience of people who use and operate the route.
Who reviews what
- Executive sponsor and operational lead
- Operational owner and participating teams
- Sending and receiving owners
- Improvement owner and executive sponsor
Candidate owners named in the scorecard, confirmed locally.
| Operating signal | Executive question | Candidate owner | Suggested review point |
|---|---|---|---|
| Prevention reliability | Are approved preventive steps usable and consistently supported in the real work environment? | Executive sponsor and operational lead | At campaign launch and close |
| Readiness | Can the right team, tool, information, and backup be reached when needed? | Operational owner and participating teams | At a locally defined cadence |
| Continuity across settings | Can people and teams see who owns the next step when responsibility crosses a setting or service? | Sending and receiving owners | At a locally defined cadence |
| Learning system | Are recurring patterns translated into owned improvements? | Improvement owner and executive sponsor | Until action is verified |
Figure 5
Control points for a reliable prevention and follow-up chain
| Control point | Risk if missing | Owner | Evidence of control |
|---|---|---|---|
| Pregnancy planning review for medications with potential fetal risk | Exposure continues without a planning conversation | Chief pharmacy officer and primary care medical director | Share of eligible patients with documented planning review |
| Folic acid counseling before pregnancy for high-risk medication users | Supplementation starts after the window associated with benefit | Neurology and women’s health service leads | Share of patients counseled and prescribed before conception |
| Newborn screening referral tracked to diagnosis | Referred infants are lost before diagnostic assessment | Newborn screening coordinator | Share of referred infants with completed diagnostic evaluation |
| Early intervention referral tracked to enrollment | Families are referred but never evaluated or enrolled | Neonatal intensive care follow-up lead and early intervention liaison | Referral, evaluation and enrollment rates stratified by race, ethnicity and payer |
| Genetic counseling capacity matched to testing | Results reach families without interpretation or support | Genetics service line leader | Wait time for genetic counseling and counselor-to-test ratio |
| Board reporting of cascade measures | Losses at each step stay invisible to leaders | Chief quality officer | Quarterly cascade report with stratified results |
Control points derived from the cited evidence [1], [2], [4], [5], [6], [15] and this brief’s executive guidance.
Data note. Each row is a control to verify, not a measured result.
Limitation. Owners and evidence of control must follow local policy and applicable requirements.
Public communication
Communicating prevention early and clearly
Low awareness is the most consistent communication finding. In Australia, 67% of surveyed adults had not heard of preconception care or were unsure.[7] In Ethiopia, only 8.9% of pregnant women showed good knowledge of periconceptional folic acid supplementation.[10] The authors call for health education integrated within antenatal care and family planning services.[10] Prevention messages that depend on people seeking them out will miss many of those who need them most.
Messages need to reach people before pregnancy, not only during it. The antiseizure medication study found that benefit was associated with starting high-dose folic acid before pregnancy, not after.[6] For people taking medications with potential fetal risk, communication about planning should be part of routine prescribing and review.[5][6] That includes non-pregnant people who are not using contraception.[5] Pharmacists and prescribers can raise the topic at refill or review without making it a separate visit.
Partners are part of the audience. The Indonesian study identified spousal communication as a pivotal factor in men’s involvement in preconception care.[9] Its authors recommend targeted educational campaigns and accessible services to address cultural norms, financial constraints and limited awareness.[9] Campaigns that speak only to women may miss the household conversations where decisions are made. Messages written for couples, and offered at marriage, contraception or fertility visits, can reach both partners at a moment when planning is already on their minds.
Families also need clear communication after a positive screen or diagnosis. The Iranian hearing screening study emphasizes targeted follow-up and early intervention for high-risk infants.[4] In the fragile X pilot, caregivers’ concerns shifted from motor development to communication development over the first year.[3] Communication that anticipates those concerns can help families stay engaged with early intervention. Families should hear, in plain terms, why services are worth starting before delays become visible.
Communication with boards should be equally direct. Cascade measures such as referral, evaluation and enrollment show exactly where families are lost.[1][2] Reporting those measures by group, and showing what changed after each improvement cycle, gives leaders and communities a credible view of progress. Plain-language summaries for families can explain what each step involves and whom to contact when a referral stalls.

Executive guidance · 90-day plan
Move from listening to a verified improvement in 90 days.
The time boxes below are a management framework, not a clinical timeline. Adjust them to risk, scope, governance, resources, stakeholder participation, and applicable review requirements.
Ninety days, three moves
- Days 1–30See the current route
- Days 31–60Build the reliable path
- Days 61–90Make the change visible
Days 1–30 · Listen and map
See the current route
- Name an executive sponsor and an operational owner.
- Listen to people using the route and representative frontline teams.
- Map how National Birth Defects Prevention Month communications connect to real entry points, owners, transitions, and escalation.
- Select one recurring barrier that the organization can responsibly address.
Days 31–60 · Design and test
Build the reliable path
- Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.
- Validate the design with every sending and receiving team involved.
- Test one continuity handoff across representative settings and verify that the next owner is visible.
- Test the route in more than one representative setting or operating period where practical.
Days 61–90 · Implement and verify
Make the change visible
- Launch the redesigned route with a small set of locally defined measures.
- Review unresolved work and recurring friction using a learning approach.
- Correct implementation barriers and record who owns each remaining dependency.
- Report what changed, what evidence was reviewed, and what still requires live oversight.
Figure 6
The 90-day plan on one timeline
The 90-day plan from this brief drawn as a timeline: each action sits in the 30-day window the plan assigns it. The full wording of each action is in the figure data and in the plan above.
Data note. Time boxes are a management framework, not a clinical timeline.
Limitation. Durations are uniform 30-day windows; real tasks may span windows.
Figure data (12 rows)
| Window | Action |
|---|---|
| Days 1–30 · Listen and map | Name an executive sponsor and an operational owner. |
| Days 1–30 · Listen and map | Listen to people using the route and representative frontline teams. |
| Days 1–30 · Listen and map | Map how National Birth Defects Prevention Month communications connect to real entry points, owners, transitions, and escalation. |
| Days 1–30 · Listen and map | Select one recurring barrier that the organization can responsibly address. |
| Days 31–60 · Design and test | Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal. |
| Days 31–60 · Design and test | Validate the design with every sending and receiving team involved. |
| Days 31–60 · Design and test | Test one continuity handoff across representative settings and verify that the next owner is visible. |
| Days 31–60 · Design and test | Test the route in more than one representative setting or operating period where practical. |
| Days 61–90 · Implement and verify | Launch the redesigned route with a small set of locally defined measures. |
| Days 61–90 · Implement and verify | Review unresolved work and recurring friction using a learning approach. |
| Days 61–90 · Implement and verify | Correct implementation barriers and record who owns each remaining dependency. |
| Days 61–90 · Implement and verify | Report what changed, what evidence was reviewed, and what still requires live oversight. |
Executive guidance · Leadership close
Carry one accountable improvement beyond the campaign window.
Recognition matters. It becomes durable when leaders also listen, clarify the route, support the people operating it, close an identified gap, and report the result without claiming more than the evidence supports.
Leadership commitment
Listen to the people closest to the route, assign one barrier, and verify the change.
Executive action kit · Month observance
Turn National Birth Defects Prevention Month into accountable action.
Use the observance to test whether prevention, readiness, escalation, and learning operate as one connected system.
Leadership focus
Use this observance to examine trustworthy information, prevention access, and community connection. Select one verified barrier, assign an accountable owner, and carry the improvement beyond the campaign window.
Workforce lens
Ask whether staffing, role clarity, training, tools, workload, and escalation support the people operating the maternal, perinatal, escalation, and continuity pathway.
Patient and community lens
Make the approved first step clear. Test whether a person can move from information to an acknowledged next action without navigating conflicting instructions.
Equity and access lens
Review listening, respectful treatment, language access, transportation, digital access, and variation in experience using locally appropriate data and protected feedback.
Five-minute briefing
Inspect the operating sequence
Listen with patients, families, maternity teams, emergency services, ambulatory partners, and community supports. Find one a concern that is not heard, an escalation that lacks ownership, or a transition that loses context, then test the locally approved route from entry through acknowledged follow-through.
- Identify the concern
- Activate prevention
- Protect continuity
- Escalate and respond
- Review and improve
Leadership actions for this week
- Name an executive sponsor and frontline operating owner.
- Ask people using and operating the pathway where ownership becomes unclear.
- Test one representative route from first question to acknowledged next step.
- Select one barrier that can be corrected without overstating the evidence.
- Set a review date and define how completion will be verified.
Candidate measures
Define every numerator, denominator where relevant, owner, data source, exclusions, cadence, and limitation locally. These are management prompts, not external benchmarks.
- Locally defined control checks, barriers, exceptions, and corrective-action status.
- Readiness checks, unavailable resources, response barriers, and escalations.
- Locally defined transition acknowledgment, unresolved work, repeat contacts, escalation, and experience feedback.
Department readiness checklist
- The public and staff entry points match the actual approved process.
- A specific role accepts each request, referral, or escalation.
- Handoffs include acknowledgment and a visible unresolved state.
- Language, disability, digital, transportation, and trust barriers receive explicit review.
- Communications do not introduce unsupported themes, statistics, or clinical advice.
- A named leader will review what changed after the observance.
Intended audiences
- Executive and Operational Leaders
- Public Health and Community Partners
Staff communication template
During National Birth Defects Prevention Month, our organization will connect awareness with a practical review of the maternal, perinatal, escalation, and continuity pathway. Use approved information, identify the correct entry point, confirm ownership when work moves, protect privacy, and escalate unresolved barriers through local channels.
Community communication template
National Birth Defects Prevention Month is an opportunity to share trustworthy information and make the next step easier to find. Use our approved channels for information and support. If a request changes hands, our goal is to keep ownership and follow-through visible.
Measurement worksheet
- Signal
- What observable condition will show whether the route works?
- Definition
- What is included, excluded, and counted?
- Owner
- Who reviews the signal and acts on exceptions?
- Cadence
- When will leaders review it?
- Equity check
- Which differences require protected, locally appropriate review?
- Closure
- What evidence will confirm the improvement was completed?
- Editorial review
- Completed
- Source records
- 2 listed under Authoritative resources
- Review standard
- Sourced facts remain separated from original executive guidance
- Clinical boundary
- No new statistical or clinical claim was added by this action kit
Sources and content boundary
Authoritative resources
Use note: All operating models, measures, scorecard questions, and action steps are original executive guidance. This article supports leadership planning and education. It does not replace clinical judgment, emergency procedures, legal advice, professional standards, organizational policy, or applicable federal, state, and local requirements.
Peer-reviewed references
References
Fifteen peer-reviewed sources, newest first. Each was individually verified through authenticated academic research databases. Bracketed numbers in the text link here; the original executive guidance on this page carries no citations because it is guidance, not a sourced claim. Sources last checked in those databases on .
- 1.Fraiman YS, Keith JF, O’Donoghue AL, Barfield W, Rosenfeld L, Diop H, et al. Inequities Along the Early Intervention Care Cascade for Very Preterm Infants. JAMA Pediatrics. 2026;180(7):767. https://doi.org/10.1001/jamapediatrics.2026.1822
- 2.Peacock-Chambers E, Gu KQ, Miller E, Shieh MS, Jurkowski BL, Palmer S, et al. Early Intervention Enrollment Among Substance-exposed Infants in Massachusetts: A Population-level Analysis. Journal of Developmental & Behavioral Pediatrics. 2026;47(5):e532-e537. https://doi.org/10.1097/dbp.0000000000001486
- 3.Scott S, Okoniewski KC, Edwards A, Wheeler AC. From Concerns to Care: Understanding Parental Priorities and Access to Early Intervention for Infants With Fragile X Syndrome. Journal of Intellectual Disability Research. 2026:jir.70080. https://doi.org/10.1111/jir.70080
- 4.Bayat A, Saki N, Javadi M, Nikakhlagh S, Amiri M. Universal newborn hearing screening in Southwest Iran: coverage, risk factors, and outcomes in a large-scale population. European Archives of Oto-Rhino-Laryngology. 2026. https://doi.org/10.1007/s00405-026-10658-2
- 5.Qato DM, Ozenberger K, Li Q, Steinberg I. Use of prescription medications potentially harmful during pregnancy among women of reproductive age by pregnancy status and contraceptive use in the United States, 2009–2020. Reproductive Health. 2026;23(1):182. https://doi.org/10.1186/s12978-026-02409-7
- 6.Sun Y, Alvestad S, Cohen JM, Igland J, Gilhus NE, Vegrim HM, et al. Timing of high-dose folic acid supplementation in the periconceptional period among women taking antiseizure medications and risk of major congenital anomalies: a target trial emulation. Journal of Neurology, Neurosurgery & Psychiatry. 2026;97(6):542-552. https://doi.org/10.1136/jnnp-2025-337395
- 7.Haas M, Church J, Dorney E, Street DJ, Black KI. Understanding Preferences for Preconception Care in Australia: Insights From a Discrete Choice Experiment. Health Expectations. 2026;29(1):e70593. https://doi.org/10.1111/hex.70593
- 8.Steel A, Schoenaker D, Harnett J, Adams J. The Health, Wellbeing and Health Service Use of Women Attempting or Planning Pregnancy: A Nationwide Cross‐Sectional Survey of Australian Women. Birth. 2026:birt.70088. https://doi.org/10.1111/birt.70088
- 9.Muhamad RS, Widyasari A, Sangun DIE, Ekawati FM. Males’ perception and involvement in preconception care in Indonesian primary care in Bantul region, Yogyakarta. Journal of Family Medicine and Primary Care. 2026;15(5):2040-2045. https://doi.org/10.4103/jfmpc.jfmpc_378_25
- 10.Girma T, Hibstu DT, Amare B, Garolla G. The critical gap in prevention: knowledge of periconception folic acid supplementation and its predictors among pregnant women in Ethiopia. Maternal Health, Neonatology and Perinatology. 2026;12(1):9. https://doi.org/10.1186/s40748-026-00254-x
- 11.Lins TIDS, Caminha MDFC, Marinho GA, Silva SLD, Arruda IKGD, Freitas CFD, et al. Factors associated with folic acid deficiency in pregnant women and its repercussions in the newborn: a cross-sectional study. Revista Gaúcha de Enfermagem. 2026;47:e20250182. https://doi.org/10.1590/1983-1447.2026.20250182.en
- 12.Pokhrel A, Bhatta B, Adhikari A. Compliance to iron folic acid supplementation and its associated factors among postpartum mothers of Bharatpur, Nepal: a cross-sectional study. BMJ Public Health. 2026;4(3):e003563. https://doi.org/10.1136/bmjph-2025-003563
- 13.Coffran E, Hartman TR, Madden A, Mani A, Conway L, Valverde KD. Exploring Current Perspectives on a Doctor of Philosophy Degree in Genetic Counseling. Journal of Genetic Counseling. 2026;35(4):e70276. https://doi.org/10.1002/jgc4.70276
- 14.Sebby M, McConachie L, Wetherill L, Delk P, Hopewell EL. Teaching Cell and Gene Therapy in Genetic Counseling Programs: Survey Findings and Suggested Practical Resources for Integration. Journal of Genetic Counseling. 2026;35(5):e70295. https://doi.org/10.1002/jgc4.70295
- 15.Tchaicha S, Van Hulle J, Brilstra E, Brunklaus A, Cantalupo G, Geroldinger M, et al. Genetic testing practices across European epilepsy centers: An ERN EpiCARE survey. Epilepsia Open. 2026:epi4.70304. https://doi.org/10.1002/epi4.70304
Claim-to-source matrix
What each source supports
Every sourced claim in the new sections maps to the references that support it, the section where it is used, and the limitation a reader should keep in mind. Original executive guidance carries no sources because it is guidance, not a finding.
| Claim group | Sources | Years | Used in | Limitation |
|---|---|---|---|---|
| Early intervention care cascade and racial and ethnic inequity | [1] | 2026 | Equity and trust | Massachusetts very preterm infants born 2012 to 2019; associations attenuated with social adjustment. |
| Referral-to-enrollment gap for substance-exposed newborns | [2] | 2026 | Continuum of care | One state; diagnosis codes used to identify exposure. |
| Early intervention access after newborn diagnosis of fragile X syndrome | [3] | 2026 | Continuum of care | Small pilot program sample; mixed methods. |
| Newborn hearing screening coverage and prevalence | [4] | 2026 | Current evidence | One Iranian province; high consanguinity limits generalizability. |
| Use of prescription medications with potential fetal risk | [5] | 2026 | Current evidence | Self-reported 30-day medication use in national survey cycles. |
| Timing of high-dose folic acid with antiseizure medications | [6] | 2026 | Continuum of care | Target trial emulation with Nordic register data; residual confounding possible. |
| Awareness and preferences for preconception care | [7] | 2026 | Access | Online discrete choice experiment; stated, not observed, preferences. |
| Health service use among women planning pregnancy | [8] | 2026 | Access | Small subgroups within one 2022 survey. |
| Men’s involvement in preconception care | [9] | 2026 | Equity and trust | 100 men at three primary care centers in one region. |
| Knowledge of periconceptional folic acid | [10] | 2026 | Current evidence | Single teaching hospital antenatal clinic. |
| Folic acid deficiency and associated factors | [11] | 2026 | Current evidence | Secondary analysis at one referral hospital. |
| Iron and folic acid compliance and antenatal contact | [12] | 2026 | Access | Cross-sectional; self-reported compliance in one city. |
| Genetic counselor views on doctoral training | [13] | 2026 | Human infrastructure | Voluntary survey of 514 counselors. |
| Cell and gene therapy training in genetic counseling programs | [14] | 2026 | Human infrastructure | Program leadership survey; 69.2% response. |
| Genetic testing and counseling access in expert centers | [15] | 2026 | Access | European epilepsy centers only; self-reported practices. |

About the author
Greg Wahlstrom
MBAHCM
President and Chief Executive Officer, The Healthcare Executive
View Greg’s profile©2014 – 2026 The Healthcare Executive. All rights reserved.

